Medscape Conference Coverage, based on selected sessions at the:

48th Annual ICAAC/IDSA 46th Annual Meeting: A Joint Meeting of the American Society for Microbiology and the Infectious Diseases Society of America

October 25 - 28, 2008; Washington, DC

This activity is not sanctioned by, nor a part of, the American Society for Microbiology or the Infectious Diseases Society of America. Conference news does not receive grant support and is produced independently.

CME on This Topic

Conference News

Single-Dose Intravenous Peramivir Effective

A Japanese phase 2 study demonstrates early relief of symptoms and a favorable adverse-effect profile in a nonoral treatment.
Medscape Medical News, October 30, 2008
Prulifloxacin Appears Safe, Fast, Effective

In a phase 3 study, treatment with prulifloxacin resulted in resolution of symptoms within about 24 hours; adverse effects were similar to placebo.
Medscape Medical News, October 29, 2008
Bone Mineral Density Loss and Antiretrovirals

A pair of studies offer an explanation for the loss in bone mineral density that many HIV-infected patients experience and suggest possible interventions to reverse the process.
Medscape Medical News, October 28, 2008
Linezolid-Resistant S aureus in Critically Ill Patients

Swift implementation of barrier precautions and reductions in linezolid use helped a Madrid hospital contain the outbreak.
Medscape Medical News, October 28, 2008
Anti-HIV Monoclonal Antibody Shows Promise

An interim analysis of early-phase trials looks promising, but hurdles remain.
Medscape Medical News, October 28, 2008
Darunavir, Atazanavir Comparable to Lopinavir

At week 96 in the ARTEMIS and CASTLE trials, both darunavir and atazanavir with ritonavir were noninferior to or better than lopinavir plus ritonavir in HIV-infected patients who have not previously received treatment.
Medscape Medical News, October 28, 2008
Raltegravir Effective in Treatment-Naïve Patients

Raltegravir, the first-in-class integrase inhibitor, continues to impress with its safety and efficacy, this time with 48-week data from treatment-nave patients.
Medscape Medical News, October 27, 2008
5-Hour Diagnostic Test for MRSA

Diagnostic technology that uses bacteriophages has the potential to quickly identify pathogens and their drug sensitivity to better guide therapy.
Medscape Medical News, October 26, 2008
Enhanced Surveillance Identifies More C difficile Cases

Expanded surveillance criteria for community- and healthcare-facility-associated Clostridium difficile infection identified more cases of the infection than did standard criteria.
Medscape Medical News, October 26, 2008

Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Society for Microbiology or the Infectious Diseases Society of America. These materials and the related activity are not sanctioned by the American Society for Microbiology, the Infectious Diseases Society of America, or the commercial supporter of the conference and do not constitute an official part of that conference.